Why Is TWIST BIOSCIENCE COR (TWST) Stock Up Today?
By the Top Tier Newswire AI Desk · August 20, 2026 at 12:03 AM ET · reviewed against 7 wire stories
TWIST BIOSCIENCE COR (TWST) is up +22.64% in the latest session. Our newswire has captured 7 stories on TWST across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
TWST stock is up 22.64% at $142.39 as of the close of the session, driven by news of its involvement in evaluating Anthropic’s AI capabilities in drug design. The company's collaboration with Anthropic has sparked investor interest, particularly after the AI firm announced that Twist Bioscience is one of its independent evaluators. This development has elevated TWST to its highest close since 2021, despite the company’s unprofitable status and a recent short report from Scorpion Capital.
What Happened
Twist Bioscience announced it is assisting Anthropic in testing whether its AI model, Claude, can accelerate the drug-design process. The company filed a prospectus supplement to register the resale of shares, indicating increased activity in its capital structure. Independent testing by Adaptyv Bio and Twist Bioscience showed that Claude-designed proteins successfully bound to 14 of 15 targets. This has drawn attention from both the biotech and AI sectors, with some analysts noting a ripple effect on AI-linked biotech peers. Meanwhile, Martin Shkreli, known as “Pharma Bro,” criticized Anthropic’s claims, calling the work unimpressive. Despite this, the stock has surged on the strength of the collaboration and positive sentiment.
What The Data Shows
Over the last eight sessions, TWST has risen 21.3% from $117.43 to $142.39, with $142.39 marking a new 52-week high. The stock printed 17 fresh 52-week highs on August 20. Insider sales have been active recently, with the CEO and a director selling shares totaling $34.4 million in the last 90 days. The stock has a market cap of $7.8 billion and a beta of 2.16, reflecting its volatility. While revenue has grown 19.2% in the trailing twelve months, the company remains unprofitable with an EPS of -2.23 and a net margin of -31.7%.
What To Watch
Investors should monitor the company’s upcoming earnings report if one is scheduled. Additionally, the breadth of coverage and investor sentiment surrounding the AI-biotech intersection may influence TWST’s near-term trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
An update from Twist Bioscience ( ($TWST) ) is now available. Twist Bioscience Corporation has filed a prospectus supplement to register the resale of shares issued...
24d agoMarketWatchBULLISH 63Product/PR
Twist Bioscience on Track for Highest Close Since 2021 on Work With Anthropic
24d agoSeeking AlphaBULLISH 67Product/PR
Twist Bio jumps sending AI-linked peers higher after Anthropic announcement
Twist Bioscience (TWST) stock jumped, lifting its AI-linked biotech peers after Anthropic said that the company is one of its independent evaluators. Read more here.
24d agoInvesting.com MarketsNEUTRAL 50General
Why is Twist Bioscience stock surging today?
Why is Twist Bioscience stock surging today?
25d agoMarketWatchBULLISH 58Product/PR
Twist Bioscience Assists Anthropic in Testing Whether Claude Can Accelerate Drug-Design Process
25d agoStocktwits NewsNEUTRAL 48General
‘Pharma Bro’ Martin Shkreli Slams Anthropic’s Claude Drug-Discovery Claims: ‘This Is Not Impressive Work’
Claude-designed proteins successfully bound to 14 of 15 targets in independent testing by Adaptyv Bio and Twist Bioscience.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →